Analyst Information
Yasmeen Rahimi, Ph.D.Sr. Research Analyst![]() Yasmeen Rahimi is a director and senior research analyst at Piper Sandler covering biotechnology. Prior to joining Piper Sandler in July 2020, Rahimi was a senior research analyst and co-head of biotechnology equity research team at ROTH Capital Partners. Before that, she worked as an equity research associate at H.C. Wainwright & Co. and Guggenheim Securities. Prior to making the transition to Wall Street, Rahimi was a research scientist at Shire Pharmaceuticals where she developed biomarker strategies for a number of rare disease programs; she has an extensive expertise in liver metabolism. Rahimi trained as a postdoctoral fellow at Yale University in the laboratory of Gerald Shulman after completing her Ph.D. from Indiana University School of Medicine. In addition, she has a M.S. in Bioanalytical Chemistry from Purdue University and a joint B.A. in German and Chemistry from Butler University. |
Universe Coverage: Healthcare: Biotechnology | |
ETNB | 89bio, Inc. |
ALBO | Albireo Pharma, Inc. |
ALT | Altimmune, Inc. |
AMRN | Amarin Corp. Plc |
ARCT | Arcturus Therapeutics Holdings, Inc. |
AXLA | Axcella Health, Inc. |
CBAY | CymaBay Therapeutics Inc. |
ENTA | Enanta Pharmaceuticals, Inc. |
IMUX | Immunic, Inc. |
ICPT | Intercept Pharmaceuticals, Inc. |
LMNL | Liminal BioSciences, Inc. |
LUMO | Lumos Pharma, Inc. |
MDGL | Madrigal Pharmaceuticals, Inc. |
MTNB | Matinas BioPharma Holdings, Inc. |
MIRM | Mirum Pharmaceuticals, Inc. |
NGM | NGM Biopharmaceuticals, Inc. |
PTGX | Protagonist Therapeutics, Inc. |